Private Equity
Trump's drug cost concern an opportunity for Indian firms
23 Jan 2017
"If controlling cost of drugs is a priority for the new administration, US cannot write off Indian pharmaceutical products. At the price we offer, US companies cannot produce them in that country,".
Vrinda Mathur
Partner, Grant Thornton Bharat LLP
This article appeared in My Digital FC on 23rd January, 2017.
Also appears under...